Please login to the form below

Not currently logged in
Email:
Password:

US market

This page shows the latest US market news and features for those working in and with pharma, biotech and healthcare.

Allergan’s abicipar matches AMD blockbuster Lucentis in phase III

Allergan’s abicipar matches AMD blockbuster Lucentis in phase III

Both studies will continue for another year. Lucentis – sold by Roche in the US and Novartis in Europe and other markets – and Regeneron’s Eylea (aflibercept) currently dominate the wet AMD ... market. Last year, Roche recorded US sales of its drug

Latest news

  • Roche keeps Venclexta train rolling with new leukaemia filing Roche keeps Venclexta train rolling with new leukaemia filing

    Roche and partner AbbVie have filed their fast-growing blood cancer drug Venclexta in the US as a first-line treatment for acute myelogenous leukaemia (AML), a key new indication for ... Roche's Genentech unit is collaborating with the company on

  • New ABPI president pledges closer collaboration with NHS New ABPI president pledges closer collaboration with NHS

    s slow uptake of new medicines and potential isolation from the EMA approvals process could see the country relegated in importance as a launch market. ... Writing on behalf of 10 US-headquartered pharma companies, he said that “the UK pharmaceutical

  • The year of the blockbuster The year of the blockbuster

    Trial results, regulatory  data, market projections and regulatory designations were all taken into account. ... Sublocade (buprenorphine) from Indivior:Sublocade, having been launched in the US in March, could disrupt the market for medication-assisted

  • AbbVie, Roche get FDA OK for broader use of Venclexta AbbVie, Roche get FDA OK for broader use of Venclexta

    A regimen based on AbbVie/Roche’s Venclexta for chronic lymphocytic leukaemia (CLL) - which has been described as ‘practice-changing’ - has been approved in the US. ... Roche's Genentech unit is collaborating with the company on Venclexta's

  • The call for a more strategic medical affairs community The call for a more strategic medical affairs community

    We shouldn’t form our own voice in a vacuum without the contributions of commercial and R&D and the patient or market access. ... They should be helping us to say how we can become better partners.

More from news
Approximately 1 fully matching, plus 811 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    In addition the US stock market excited by the prospect of changes in corporate tax and greater government investment driving growth has risen to new highs. ... 1, 410 (upfront 80). WuXi Biologics and Gloria Pharma (CN). Arcus Biosciences (US).

  • Hacking Innovation Hacking Innovation

    invent an anti-pollution product, but also to prepare and deliver their pitch for how the product could deliver real change should it be chosen to hit the Chinese market. ... He explains: “We look for life-changing creativity that we can put into

  • Deal Watch - May 2017 Deal Watch - May 2017

    For Sawai this acquisition represents an entry into the US market and as such the current facilities and management will be retained. ... Medical devices and diagnostics with sales of $3.7bn. 24, 000. Medtronic (US/IE).

  • Making digital health personal Making digital health personal

    Progress tracking: A case study. This case study looks at a native app developed in the US market for a local pharma client that allows patients to plan their medication schedule;

  • Speaking the language of effective communications Speaking the language of effective communications

    That's the same on both sides of the ocean. In the US we're looking very much to the models in the EU about how market access is working, because ... In the US that's less often the case, unless people work in a global team.

More from intelligence
Approximately 0 fully matching, plus 39 partially matching documents found.

Latest appointments

  • Industry round up: appointments Industry round up: appointments

    Prior to this, Jenkins spent 17 years at GlaxoSmithKline (GSK) in the UK and US. ... UK. Vu, whose new post will see him further expand Concept’s presence in the US market, joins the company with over 15 years’experience in both business development

  • Open Health creates new role Open Health creates new role

    Joining the agency with twenty years’biopharmaceutical industry experience, Jones’expertise lies in market access, therapy launch and patient centric services. ... Creating a unique role within our field of expertise will enable us to offer a market

  • W2O bolsters its commercialisation offering W2O bolsters its commercialisation offering

    W2O bolsters its commercialisation offering. Rita Glaze joins the firm as leader of value, pricing and market access practice. ... Joining the network from Edelman, Glaze previously led the design and implementation of its US market access communications

  • Amra appoints new VP of North American sales Jeremy Edwards Amra appoints new VP of North American sales Jeremy Edwards

    Body composition analysis group, Amra, has made a trio of new-hires to support its growth and expansion of its operations into the US. ... expand the US market.”.

  • Portland Health appoints Alfred Jackson as a partner Portland Health appoints Alfred Jackson as a partner

    He said: “The opportunity to help Portland expand its impressive health footprint to the US market is an incredible opportunity. ... agency experience, senior leadership and strategic relationships across the health and government sectors to deepen our

More from appointments
Approximately 1 fully matching, plus 24 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics